GE

255.78

+1.67%↑

RTX

139.19

+0.19%↑

CAT

353.42

+1.42%↑

BA

210.99

+0.98%↑

HON

228.84

+1.06%↑

GE

255.78

+1.67%↑

RTX

139.19

+0.19%↑

CAT

353.42

+1.42%↑

BA

210.99

+0.98%↑

HON

228.84

+1.06%↑

GE

255.78

+1.67%↑

RTX

139.19

+0.19%↑

CAT

353.42

+1.42%↑

BA

210.99

+0.98%↑

HON

228.84

+1.06%↑

GE

255.78

+1.67%↑

RTX

139.19

+0.19%↑

CAT

353.42

+1.42%↑

BA

210.99

+0.98%↑

HON

228.84

+1.06%↑

GE

255.78

+1.67%↑

RTX

139.19

+0.19%↑

CAT

353.42

+1.42%↑

BA

210.99

+0.98%↑

HON

228.84

+1.06%↑

Search

Ocugen Inc

Fermé

1.05 9.38

Résumé

Variation du prix de l'action

24h

Actuel

Min

1.05

Max

1.05

Chiffres clés

By Trading Economics

Revenu

-1.5M

-15M

Ventes

717K

1.5M

BPA

-0.05

Marge bénéficiaire

-1,036.462

Employés

95

EBITDA

-350K

-14M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+566.32% upside

Dividendes

By Dow Jones

Prochains Résultats

7 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

40M

244M

Ouverture précédente

-8.33

Clôture précédente

1.05

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

Ocugen Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

6 juin 2025, 14:31 UTC

Résultats

New York State Retirement Fund Posts 5.84% Annual Investment Return

6 juin 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 juin 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6 juin 2025, 20:33 UTC

Résultats

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 juin 2025, 19:36 UTC

Market Talk

Oil Futures Post Solid Weekly Gains -- Market Talk

6 juin 2025, 19:28 UTC

Market Talk

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

6 juin 2025, 18:46 UTC

Market Talk

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

6 juin 2025, 18:02 UTC

Market Talk

U.S. Oil Rig Count Continues to Decline -- Market Talk

6 juin 2025, 16:35 UTC

Résultats

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 juin 2025, 16:34 UTC

Résultats

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 juin 2025, 16:21 UTC

Market Talk

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

6 juin 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6 juin 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 juin 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

6 juin 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6 juin 2025, 16:07 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

6 juin 2025, 16:07 UTC

Market Talk

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

6 juin 2025, 15:53 UTC

Market Talk

Mexican Inflation Seen Rising in May -- Market Talk

6 juin 2025, 15:36 UTC

Market Talk

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

6 juin 2025, 15:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6 juin 2025, 15:33 UTC

Market Talk

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

6 juin 2025, 15:16 UTC

Market Talk

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

6 juin 2025, 15:05 UTC

Market Talk

Silver at its Highest In Nearly 15 Years -- Market Talk

6 juin 2025, 14:35 UTC

Market Talk

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

6 juin 2025, 14:28 UTC

Market Talk

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

6 juin 2025, 14:28 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6 juin 2025, 14:28 UTC

Market Talk

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

6 juin 2025, 14:15 UTC

Market Talk

Oil Rises on U.S.-China Talks Optimism -- Market Talk

6 juin 2025, 14:12 UTC

Résultats

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

6 juin 2025, 14:09 UTC

Résultats

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Comparaison

Variation de prix

Ocugen Inc prévision

Objectif de Prix

By TipRanks

566.32% hausse

Prévisions sur 12 Mois

Moyen 6.33 USD  566.32%

Haut 8 USD

Bas 4 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

3 ratings

3

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

0.6818 / 0.74Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

No Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.